Eosinophilia during psoriasis treatment with TNF antagonists.
Bartosz
B
Malisiewicz
Carla
C
Murer
Jana
J
Pachlopnik Schmid
Lars E
LE
French
Peter
P
Schmid-Grendelmeier
Alexander A
AA
Navarini
D000068879:Adalimumab; D000875:Anthralin / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D047150:Eosinophil Cationic Protein / Q000097:blood; D004802:Eosinophilia / Q000139:chemically induced*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D047150:Eosinophil Cationic Protein; D000068879:Adalimumab; D000068800:Etanercept; D000875:Anthralin